These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 31436896)

  • 21. Randomized controlled trial assessing the impact of everolimus and low-exposure tacrolimus on graft outcomes in kidney transplant recipients.
    Taber DJ; Chokkalingam A; Su Z; Self S; Miller D; Srinivas T
    Clin Transplant; 2019 Oct; 33(10):e13679. PubMed ID: 31365151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. De novo tacrolimus extended-release tablets (LCPT) versus twice-daily tacrolimus in adult heart transplantation: Results of a single-center non-inferiority matched control trial.
    van Zyl JS; Sam T; Clark DM; Felius J; Doss AK; Kerlee KR; Cheung ZO; Martits-Chalangari K; Jamil AK; Carey SA; Gottlieb RL; Guerrero-Miranda CY; Kale P; Hall SA
    Clin Transplant; 2021 Dec; 35(12):e14487. PubMed ID: 34529289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients.
    Lu Z; Bonate P; Keirns J
    Br J Clin Pharmacol; 2019 Aug; 85(8):1692-1703. PubMed ID: 30950096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tacrolimus variability is associated with de novo donor-specific antibody development in pediatric renal transplant recipients.
    Solomon S; Colovai A; Del Rio M; Hayde N
    Pediatr Nephrol; 2020 Feb; 35(2):261-270. PubMed ID: 31732803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three-year outcomes of de novo tacrolimus extended-release tablets (LCPT) compared to twice-daily tacrolimus in adult heart transplantation.
    Alam A; van Zyl JS; Patel R; Jamil AK; Felius J; Carey SA; Gottlieb RL; Guerrero-Miranda CY; Kale P; Hall SA; Sam T
    Transpl Immunol; 2024 Apr; 83():102009. PubMed ID: 38325525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study.
    Gatault P; Kamar N; Büchler M; Colosio C; Bertrand D; Durrbach A; Albano L; Rivalan J; Le Meur Y; Essig M; Bouvier N; Legendre C; Moulin B; Heng AE; Weestel PF; Sayegh J; Charpentier B; Rostaing L; Thervet E; Lebranchu Y
    Am J Transplant; 2017 May; 17(5):1370-1379. PubMed ID: 27862923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Delayed Prolonged-Release Tacrolimus Initiation in De Novo Hepatitis C Virus-Negative Orthotopic Liver Transplant Recipients: A Single-Center, Single-Arm, Prospective Study.
    Lladó L; González-Castillo A; Fabregat J; Baliellas C; Ramos E; González-Vilatarsana E; Busquets J; Xiol X
    Ann Transplant; 2019 Jan; 24():36-44. PubMed ID: 30655498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of prolonged-release versus immediate-release tacrolimus in
    Kim MS; Joh JW; Kim DS; Kim SH; Choi JS; Lee J; Lee JY; Kim JM; Kwon CHD; Choi GS; Yu YD; Yoon YI; Han JH; Lee YJ; Jiang H; Kim SI
    Korean J Transplant; 2019 Jun; 33(2):20-29. PubMed ID: 35769149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial.
    Asrani SK; Wiesner RH; Trotter JF; Klintmalm G; Katz E; Maller E; Roberts J; Kneteman N; Teperman L; Fung JJ; Millis JM
    Am J Transplant; 2014 Feb; 14(2):356-66. PubMed ID: 24456026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Effectiveness of Conversion From Cyclosporine to Once-Daily Prolonged-Release Tacrolimus in Stable Kidney Transplant Patients: A Multicenter Observational Study in Japan.
    Usuki S; Uno S; Sugamori H; Tanaka H; Aikawa A
    Transplant Proc; 2018 Dec; 50(10):3266-3274. PubMed ID: 30577196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 39-month follow-up study to evaluate the safety and efficacy in kidney transplant recipients treated with modified-release tacrolimus (FK506E)-based immunosuppression regimen.
    Han DJ; Park JB; Kim YS; Kim SJ; Ha J; Kim HC; Kim SJ; Moon IS; Yang CW
    Transplant Proc; 2012 Jan; 44(1):115-7. PubMed ID: 22310592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients.
    Dugast E; Soulillou JP; Foucher Y; Papuchon E; Guerif P; Paul C; Riochet D; Chesneau M; Cesbron A; Renaudin K; Dantal J; Giral M; Brouard S
    Am J Transplant; 2016 Nov; 16(11):3255-3261. PubMed ID: 27367750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and safety of once-daily tacrolimus formulations in de novo liver transplant recipients: The PRETHI study.
    Bilbao I; Gómez Bravo MÁ; Otero A; Lladó L; Montero JL; González Dieguez L; Graus J; Pons Miñano JA
    Clin Transplant; 2023 Dec; 37(12):e15105. PubMed ID: 37615653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.
    Jain A; Reyes J; Kashyap R; Rohal S; Abu-Elmagd K; Starzl T; Fung J
    Ann Surg; 1999 Sep; 230(3):441-8; discussion 448-9. PubMed ID: 10493490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence of Renal Transplant Recipients to Once-daily, Prolonged-Release and Twice-daily, Immediate-release Tacrolimus-based Regimens in a Real-life Setting in Sweden.
    Fellström B; Holmdahl J; Sundvall N; Cockburn E; Kilany S; Wennberg L
    Transplant Proc; 2018 Dec; 50(10):3275-3282. PubMed ID: 30577197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tacrolimus: a further update of its use in the management of organ transplantation.
    Scott LJ; McKeage K; Keam SJ; Plosker GL
    Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial.
    Saliba F; Duvoux C; Gugenheim J; Kamar N; Dharancy S; Salamé E; Neau-Cransac M; Durand F; Houssel-Debry P; Vanlemmens C; Pageaux G; Hardwigsen J; Eyraud D; Calmus Y; Di Giambattista F; Dumortier J; Conti F
    Am J Transplant; 2017 Jul; 17(7):1843-1852. PubMed ID: 28133906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in
    Budde K; Rostaing L; Maggiore U; Piotti G; Surace D; Geraci S; Procaccianti C; Nicolini G; Witzke O; Kamar N; Albano L; Büchler M; Pascual J; Gutiérrez-Dalmau A; Kuypers D; Wekerle T; Głyda M; Carmellini M; Tisone G; Midtvedt K; Wennberg L; Grinyó JM
    Transpl Int; 2022; 35():10225. PubMed ID: 36017158
    [No Abstract]   [Full Text] [Related]  

  • 40. Tacrolimus prolonged release (Envarsus®): a review of its use in kidney and liver transplant recipients.
    Garnock-Jones KP
    Drugs; 2015 Feb; 75(3):309-20. PubMed ID: 25613762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.